Skip to main content

PD-L1 IHC, NSCLC Keytruda®

CPT 88360
Synonyms
  • Pembrolizumab; Programmed Death Ligand 1

Test Details

Methodology

Immunohistochemistry (IHC) using Dako Automated Link 48 platform

Result Turnaround Time

4 - 5 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Use

The Dako PD-L1 22C3 pharmDx™ kit is a qualitative assay intended for use in the detection of PD-L1 in formalin-fixed, paraffin-embedded (FFPE) in non-small cell lung carcinoma (NSCLC) using the Dako Automated Link 48 platform.

Special Instructions

PD-L1 testing will be delayed if the pathology report is not received.

Note: This test number is used for tracking oncology IHC specimens to the laboratory. Bill codes will be added when testing is complete based on the processes performed in the laboratory.

Specimen Requirements

Specimen

Formalin-fixed, paraffin-embedded (FFPE) tissue block or slides

Volume

One tissue block or five unstained, positively charged slides less than one month old

Minimum Volume

Three unstained, positively charged slides

Container

Paraffin block or unstained, positive-charged slides

Collection Instructions

Tissue should be fixed in 10% neutral-buffered formalin for no more than 72 hours. Embed in paraffin. Slides should be no more than one month old.

Storage Instructions

Refrigerate; protect from light.

Causes for Rejection

Insufficient tumor; tumor other than non-small-cell lung cancer; slides sectioned more than one month prior to test request

References

Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non−small-cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-2028.25891174
Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016 Apr 9;387(10027):1540-1550. Epub 2015 Dec 19; Online (15) 1281-7.26712084
Libtayo® [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2021.
Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1 expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase 3 trial. Lancet. 2019 April 4; Online (18) 1-12.30955977
PD-L1 IHC 22C3 pharmDX™ Interpretation Manual – NSCLC. Agilent Technologies; 2018 (U.S. publication, 2021).
PD-L1 IHC 22C3 pharmDx™ [package insert]. Agilent Technologies; P03951_20/SK00621-5 rev 2021.02.

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
452359 PD-L1 IHC, NSCLC Keytruda (R) 452360 Result 55229-9
452359 PD-L1 IHC, NSCLC Keytruda (R) 452361 % Tumor Cells Staining: % 83053-9
452359 PD-L1 IHC, NSCLC Keytruda (R) 452362 Comments: 77202-0
452359 PD-L1 IHC, NSCLC Keytruda (R) 452363 Interpretation 50595-8
452359 PD-L1 IHC, NSCLC Keytruda (R) 452364 Director Review 72486-4
Order Code452359
Order Code NamePD-L1 IHC, NSCLC Keytruda (R)
Order Loinc
Result Code452360
Result Code NameResult
UofM
Result LOINC55229-9
Order Code452359
Order Code NamePD-L1 IHC, NSCLC Keytruda (R)
Order Loinc
Result Code452361
Result Code Name% Tumor Cells Staining:
UofM%
Result LOINC83053-9
Order Code452359
Order Code NamePD-L1 IHC, NSCLC Keytruda (R)
Order Loinc
Result Code452362
Result Code NameComments:
UofM
Result LOINC77202-0
Order Code452359
Order Code NamePD-L1 IHC, NSCLC Keytruda (R)
Order Loinc
Result Code452363
Result Code NameInterpretation
UofM
Result LOINC50595-8
Order Code452359
Order Code NamePD-L1 IHC, NSCLC Keytruda (R)
Order Loinc
Result Code452364
Result Code NameDirector Review
UofM
Result LOINC72486-4